Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBIT Margin (2022 - 2025)

Arcutis Biotherapeutics has reported EBIT Margin over the past 4 years, most recently at 14.65% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 2565.0% year-over-year to 14.65%; the TTM value through Dec 2025 reached 3.3%, up 6270.0%, while the annual FY2025 figure was 3.29%, 7381.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 14.65% at Arcutis Biotherapeutics, up from 8.59% in the prior quarter.
  • Over five years, EBIT Margin peaked at 14.65% in Q4 2025 and troughed at 14448.0% in Q3 2022.
  • A 4-year average of 1551.45% and a median of 105.15% in 2023 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 1432499bps in 2023 and later soared 2537bps in 2025.
  • Year by year, EBIT Margin stood at 2310.84% in 2022, then soared by 80bps to 452.23% in 2023, then surged by 98bps to 11.0% in 2024, then skyrocketed by 233bps to 14.65% in 2025.
  • Business Quant data shows EBIT Margin for ARQT at 14.65% in Q4 2025, 8.59% in Q3 2025, and 17.93% in Q2 2025.